December 2011 in “The Diabetes Educator” The Blood Glucose Management Service improved patient safety and outcomes in managing blood sugar in hospitalized patients.
9 citations
,
March 2022 in “Journal of Chemical Information and Modeling” New inhibitors may reduce gut toxicity from cancer drugs.
May 2022 in “Голова и шея.” Checkpoint inhibitor therapy can cause skin issues, from mild rashes to severe reactions.
8 citations
,
May 2020 in “Arthritis research & therapy” DHT inhibition may increase spinal bone growth in ankylosing spondylitis.
September 2025 in “Bioengineering” The framework helps predict adverse effects of blood thinners, improving drug selection for atrial fibrillation.
54 citations
,
May 2015 in “Endocrinology” Manipulating 5α-reductase type 2 can affect liver fat production and glucocorticoid effects.
14 citations
,
September 2019 in “Eye” Some oral medications may help treat central serous chorioretinopathy, especially eplerenone, but more research is needed.
November 2024 in “Journal of Investigative Dermatology” Genetic changes in specific proteins contribute to hair loss in some women of African descent.
1 citations
,
March 2004 in “Journal of the American Academy of Dermatology” ZD1839, a cancer drug, can cause mild skin rashes that are treatable without stopping the medication.
Encapsulating hair loss drugs in cyclodextrins improves their solubility and reduces scalp irritation.
8 citations
,
July 2019 in “Pure and Applied Chemistry” Some natural compounds from Iris plants can block enzymes related to certain disorders, with a few affecting both targeted enzymes.
April 2016 in “Journal of The American Academy of Dermatology” Some blood pressure medications are linked to a higher risk of skin cancer.
January 2004 in “Pharmaceutical biotechnology” Finasteride effectively inhibits the enzyme steroid 5 alpha-reductase II.
18 citations
,
January 1999 in “CNS Drugs” Some anticonvulsant drugs can cause skin reactions, ranging from mild to severe, and managing these reactions is important for patient care.
November 2024 in “Journal of Investigative Dermatology” Secukinumab reduces immune activity in hidradenitis suppurativa skin.
1 citations
,
May 2023 in “Biochemical and Biophysical Research Communications” Blocking DKK1 with siRNA can improve hair growth.
87 citations
,
December 2015 in “Cochrane library” No single treatment is clearly effective for central serous chorioretinopathy.
October 2008 in “Clin-alert” Certain medications can reduce mortality risk in COPD patients, but others can increase risks of cardiovascular issues, postoperative delirium, and other adverse effects.
4 citations
,
August 2013 in “Case reports in dermatology” A patient with total hair loss developed vitiligo after using a treatment called DCP.
1 citations
,
September 2024 in “Journal of the American Academy of Dermatology” Farudodstat may effectively treat alopecia areata without harmful side effects.
81 citations
,
July 2008 in “The Journal of Clinical Endocrinology and Metabolism” Certain mutations in the H6PD gene cause Cortisone Reductase Deficiency by affecting hormone production.
21 citations
,
January 2021 in “Frontiers in Pharmacology” Thiopurines help treat IBD but require genetic testing to avoid side effects.
March 2026 in “Journal of the American Academy of Dermatology” The treatment significantly improved lymphocytic cicatricial alopecia symptoms in most patients.
March 2026 in “Stem Cell Reviews and Reports” July 2025 in “Ultrasound in Medicine & Biology” UTMD with diclofenac and Doxil® improves cancer treatment by boosting immune response and reducing tumor-supporting cells.
22 citations
,
March 1999 in “International Journal of Clinical Practice” Diphencyprone (DCP) is an effective treatment for severe alopecia areata and resistant warts, with some risks.
2 citations
,
September 2024 in “Internal Medicine Journal” Upadacitinib helped regrow hair and maintain ulcerative colitis remission.
9 citations
,
February 2011 in “Biologics: Targets & Therapy” Topical calcineurin inhibitors, especially 0.1% tacrolimus ointment, are effective and well-tolerated for treating cutaneous lupus erythematosus but require more research for standard treatment guidelines.
January 2011 in “Annals of dermatology/Annals of Dermatology” A woman's psoriasis improved after hepatitis C treatment with interferon, despite interferon's risk of worsening skin conditions.
December 2022 in “International Journal of Molecular Sciences” Afatinib, neratinib, and zanubrutinib could be effective against KRASG12C-mutant tumors.